Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir

Journal of Viral Hepatitis

Volumn 18, Issue 10, 2011, Pages

  Kwak, M S ^a   Choi, J W ^a   Lee, J S ^a   Kim, K A ^a   Suh, J H ^a   Cho, Y S ^a   Won, S Y ^a   Park, B K ^a   Lee, C K ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

adefovir; breakthrough; chronic hepatitis B; entecavir; lamivudine

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS B; HUMAN; LONG TERM CARE; MALE; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION;

ADENINE; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 80052860574     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01461.x     Document Type: Article

References (19)

1. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295 (1): 65-73. (Pubitemid 43042691)
2. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354 (10): 1011-1020. (Pubitemid 43357805)
3. Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004; 9 (5): 679-693. (Pubitemid 39434331)
4. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE,. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10 (5): 625-633. (Pubitemid 41224954)
5. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44 (2): 283-290. (Pubitemid 43069209)
6. Reijnders JG, Deterding K, Petersen J, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010; 52 (4): 493-500.
7. Shim JH, Suh DJ, Kim KM, et al. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology 2009; 50 (4): 1064-1071.
8. Locarnini S,. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005; 25 (Suppl. 1): 9-19. (Pubitemid 41254589)
9. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125 (6): 1714-1722. (Pubitemid 37500436)
10. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131 (6): 1743-1751. (Pubitemid 44958517)
11. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43 (6): 1385-1391. (Pubitemid 43980117)
12. Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006; 55 (10): 1488-1495. (Pubitemid 44476796)
13. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS,. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44 (3): 703-712. (Pubitemid 44433727)
14. Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48 (1): 99-108. (Pubitemid 351975535)
15. Suzuki F, Toyoda J, Katano Y, et al. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol 2008; 23 (9): 1320-1326.
16. RJ C, RE R, K P,. Four year assessment of entecavir resistance in nucleoside-naïve and lamivudine refractory patients [Abstract]. J Hepatol 2007; 46 (Suppl. 1): S294.
17. Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ,. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010; 53: 449-454.
18. Ghany MG, Doo EC,. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49 (5 Suppl.): S174-S184.
19. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ,. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45 (2): 307-313. (Pubitemid 46374587)